FDA Approves Mounjaro to Reduce Cardiovascular Risk in Type 2 Diabetes Patients
On August 28, Eli Lilly announced that the Food and Drug Administration (FDA) has approved Mounjaro (tirzepatide), a GLP-1 medication, to help lower cardiovascular risk in individuals with type 2 diabetes who are at high risk for cardiovascular events. This approval specifically targets the reduction of major adverse cardiovascular events (MACE), which are critical for this patient population. Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health, emphasized the importance of this development, stating, "For people with type 2 diabetes, heart disease is the leading cause of death, and Mounjaro now gives them a proven way to lower that risk, adding to the strong foundation it has already built in A1C and weight management." The FDA's decision was informed by the results of the SURPASS-CVOT trial, which is notable for being the first cardiovascular outcomes trial to compare two GLP-1 medications directly against each other rather than against a placebo. This trial was the largest and longest study of tirzepatide to date, involving over 13,000 participants from 30 countries and a median follow-up of four years. The findings revealed that major cardiovascular events occurred in 12.2% of participants taking Mounjaro, compared to 13.1% for those on Trulicity, indicating an 8% lower relative risk for those on Mounjaro. Mir Ali, MD, medical director at MemorialCare Surgical Weight Loss Center, expressed optimism about the findings, noting that Mounjaro may provide significant health benefits beyond its established role in managing type 2 diabetes and supporting weight loss. He remarked, "As we learn more about these medications, we are seeing that their effects may extend beyond blood sugar control and weight management." Mounjaro's dual action as a glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist helps lower blood sugar by enhancing metabolic processing and reducing liver fat accumulation. This medication works by signaling the pancreas to release insulin after meals and slowing digestion, which promotes a feeling of fullness and aids in consistent glucose absorption. The medication also appears to reduce systemic inflammation and endothelial dysfunction, contributing to improved cardiovascular health. However, Ali cautioned that further research is necessary to determine whether Mounjaro's benefits extend independently of weight loss and diabetes control. Rigved Tadwalkar, MD, a consultative cardiologist, noted that this approval provides clinicians with another treatment option that addresses multiple health concerns for patients with type 2 diabetes and elevated cardiovascular risk. He pointed out that healthcare providers are increasingly selecting diabetes therapies with a focus on long-term outcomes, such as heart attack and stroke prevention, rather than solely on blood sugar management. While the FDA's approval is a positive advancement in the treatment of type 2 diabetes and cardiovascular disease, Tadwalkar advised caution in generalizing the findings to all patients taking tirzepatide, as the study population consisted of individuals with both type 2 diabetes and established cardiovascular disease. This context is crucial for understanding the broader implications of Mounjaro's approval for various patient groups. Overall, the recognition of cardiovascular event reduction as a clinical benefit of Mounjaro may facilitate easier access to the medication through insurance and encourage healthcare providers to prioritize it over older treatments that do not offer similar cardiovascular advantages.




